Helmholtz Institute for Pharmaceutical Research Saarland (HIPS)

What Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) does

HIPS (Helmholtz Institute for Pharmaceutical Research Saarland) is a public, non-profit research institute founded in 2009 in Saarbrücken, Germany, operating as a site of the Helmholtz-Zentrum für Infektionsforschung GmbH (HZI) in cooperation with Saarland University. Its mission is to develop novel anti-infectives to address antimicrobial resistance, combining microbial natural product discovery (with particular specialization in myxobacteria), structure-based drug design and optimization, drug delivery across biological barriers, and drug bioinformatics. The institute is organized across seven departments — Microbial Natural Products, Drug Design and Optimisation, Drug Delivery across Biological Barriers, Clinical Bioinformatics, Drug Bioinformatics, Anti-infectives from Microbiota, Antimicrobials through Chemoenzymatic Synthesis, and Synthetic Biology of Natural Products — and operates core technology platforms including NMR spectroscopy, ADMET profiling, zebrafish facilities, advanced imaging, analytics, and high-throughput robotics.

The institute's technology stack integrates proprietary natural product libraries, 3D bioprinting of bacterial biofilms on lung cells, nanoparticle and temperature-controlled drug delivery systems, dynamic combinatorial chemistry, and AI/ML-driven bioinformatics pipelines for drug target identification. HIPS hosts the PharmaScienceHub cooperation platform (with Saarland University) and the MICROBELIX citizen science initiative, and has spawned spin-off companies including MyxoTech (small molecule libraries from myxobacteria) and supported Myxobiotics (via INCATE incubator).

HIPS generates no commercial product revenue. Its operating budget is funded primarily by the German Federal Ministry of Education and Research (BMBF) through the Helmholtz Association, supplemented by federal budget allocations (notably €47M approved in December 2020 for expansion), third-party grants from sources including CARB-X, the Bill & Melinda Gates Foundation, the European Research Council, and the German Center for Infection Research (DZIF), and industry collaboration agreements with partners such as BioVersys, Beiersdorf, and Terrapeutics Pharma. The institute's go-to-market model is partnership-driven: research outputs are disseminated through scientific publications, technology transfer, licensing, and spin-off formation rather than direct sales.

Name

Helmholtz Institute for Pharmaceutical Research Saarland (HIPS)

Legal name

Helmholtz-Zentrum für Infektionsforschung GmbH (HZI)

Website

https://helmholtz-hips.de

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

251–500 employees

Short description

HIPS is a public, non-profit research institute in Saarbrücken, Germany, operating under the Helmholtz Association (HZI) and Saarland University to discover novel anti-infectives. It combines microbial natural product research, medicinal chemistry, drug delivery, and bioinformatics, funded by government grants and industry partnerships.

Ownership category

akta.pro rank

Headquarters

HQ city

Saarbrücken

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations

Revenue model

1. Public Research Funding: HIPS operates as a public research institute funded primarily by government sources including the Federal Ministry of Education and Research (BMBF), with additional support from the Helmholtz Association. The institute does not generate commercial revenue from product sales.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

HIPS is a non-profit pharmaceutical research institute that discovers and develops novel anti-infective therapies. It combines natural product-based drug discovery, medicinal chemistry, computer-aided drug design, and innovative drug delivery systems to translate microbiological findings into new drug candidates. The institute operates as a site of the Helmholtz Centre for Infection Research (HZI) in partnership with Saarland University.

Product overview

HIPS is a research institute focused on pharmaceutical research for novel anti-infectives, combining state-of-the-art medicinal chemistry and natural product-based research with innovative drug delivery approaches. The institute operates across four research areas: Microbial Natural Products, Drug Design and Optimization, Biological Barriers and Delivery, and Drug Bioinformatics. HIPS offers access to core technologies including Zebrafish Facility, NMR Spectroscopy, ADMET testing, Imaging, Analytics, and Robotics & Liquid Handling. The institute also hosts the PharmaScienceHub cooperation platform and MICROBELIX citizen science initiative. Research tools include proprietary bioinformatics software and the DataSAIL AI evaluation system.

Differentiator

Problem solved

Functional benefit

Brands

• PharmaScienceHub: A cooperation platform of Saarland University and HIPS to accelerate drug discovery development and bridge translational gap in anti-infective research.
• MICROBELIX

Products and services

• PharmaScienceHub A cooperation platform that connects academic and industrial researchers with HIPS capabilities to advance anti-infective drug discovery projects through structured collaboration.
• HIPS Software Tools (DataSAIL) A bioinformatics and cheminformatics software suite that supports compound selection, data analysis, and machine-learning workflows for pharmaceutical research, offered to the scientific community.
• MICROBELIX A citizen science initiative engaging the public in sampling and analysing microorganisms from everyday environments to discover new antibiotics and natural product producers.
• Zebrafish Infection Model Service A research service offering in vivo efficacy and toxicity testing using zebrafish infection models for anti-infective compound screening, available to academic and industrial partners.
• 3D Bioprinting Infection Model A service utilizing 3D bioprinting technology to create physiologically relevant infection models for evaluating anti-infective compounds, offered to external research collaborators.
• ADMET Testing Service A drug profiling service providing Absorption, Distribution, Metabolism, Excretion, and Toxicity analyses for novel anti-infective candidates for academic and industrial collaborators.
• NMR Spectroscopy Service A structural analysis service using Nuclear Magnetic Resonance spectroscopy to characterize small molecules, natural products, and drug candidates for research partners.
• Bio-Imaging Service A microscopy and imaging service for visualizing microbial infections, cellular processes, and drug-tissue interactions for collaborators.
• MyxoTech (Spin-off) A HIPS spin-off company commercializing myxobacterial natural products and related technologies developed at the institute for pharmaceutical and biotechnology applications.

Quantifiable outcome

• ChA completely prevented reinfection in mouse models vs 25% recurrence with vancomycin
• +1 more outcomes

Named customers1 record

Segments1 record

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature5 records

Partnerships

Eleven partnerships are on record, tiered major, core and minor.

• Beiersdorf AGmajorStrategic or Co-development Partner · 13 January 2026Research partnership in microbiome research to deliver new scientific insights into skin care and maintaining healthy skin.
• BioVersys AGmajorStrategic or Co-development Partner · 23 January 2024Collaboration to accelerate AMR research and development, joining forces against resistant pathogens.
• PharmaScienceHubcoreStrategic or Co-development Partner · 26 June 2023Cooperation platform between Saarland University and HIPS to accelerate drug discovery development. Acts as incubator for new drug development and strengthens networking between academic researchers and industry.
• Terrapeutics PharmamajorStrategic or Co-development Partner · 16 March 2022Cooperation agreement for joint development of novel antibiotics and RAS inhibitors for the treatment of uncurable cancers.
• Pharmaceutical Research Alliance SaarlandcoreStrategic or Co-development Partner · 29 November 2019Alliance between HIPS, Saarland University, and Leibniz Institute for New Materials (INM). Cooperation fund of €3.3 million established for joint research projects, startup financing, and joint professorships.
• Phyton BiotechmajorStrategic or Co-development PartnerTechnology transfer for Corallopyronin A, an active substance against neglected tropical diseases developed at DZIF, UKB, HIPS and HZI.
• TWINCOREmajorStrategic or Co-development PartnerCollaborative RSV research project with HZI and HIPS discovering promising drug candidates.
• Leibniz ScienceCampus Living Therapeutic MaterialsmajorStrategic or Co-development PartnerEntering second funding phase after four years of successful research on living therapeutic materials in Saarland.
• MyxoTechminorOthersNew HIPS spin-off company offering a library of novel small molecules.
• Helmholtz Centre for Infection Research (HZI)coreStrategic or Co-development PartnerParent organization - HIPS is a site of HZI. HZI provides institutional framework and research oversight.
• Saarland UniversitycoreStrategic or Co-development PartnerCo-founding partner of HIPS. Provides academic integration, professorships, and research collaboration.

Scale indicators7 records

Recent moves12 records

Expansion highlights5 records

Direct peers

• Leibniz Institute for Natural Product Research and Infection Biology (Leibniz-HKI): German Leibniz-association research institute focused on natural product discovery and infection biology — closely paralleling HIPS's myxobacteria specialization and anti-infectives mandate, and serving as the most directly comparable European peer.
• Helmholtz Centre for Infection Research (HZI): Parent organization of HIPS and Germany's flagship Helmholtz center for infection research. Direct peer in the anti-infectives, immunology, and translational infection biology space, with overlapping networks (DZIF) and research scope.
• Institut Pasteur: Internationally renowned French research institute with a long-standing mission in infectious disease and microbiology. Comparable to HIPS in combining basic anti-infective research with translational pipelines and spin-off activity.
• Swiss Tropical and Public Health Institute (Swiss TPH): Swiss research institute combining pharmaceutical R&D for tropical and neglected infectious diseases with public health. Highly comparable to HIPS in anti-infective drug development mission and public funding model.
• Fraunhofer Institute for Molecular Biology and Applied Ecology (IME): German applied research institute with pharmaceutical biotechnology, drug discovery, and translational capabilities. Comparable to HIPS in bridging academic research with industry partnerships and contract research models.
• Scripps Research: US-based non-profit research organization focused on biomedical sciences and drug discovery, including anti-infectives. Comparable to HIPS in mission, scale of researcher base, and translational output via spin-offs and licensing.
• Max Planck Institute for Infection Biology: German Max Planck research institute focused on infection biology, immunology, and pathogen research. Highly comparable to HIPS in anti-infectives focus, public funding model, and academic-industry interface.

Broad incumbents

• European Molecular Biology Laboratory (EMBL): Intergovernmental research organization for molecular life sciences with broader scope than HIPS. Overlaps in bioinformatics, structural biology, and infection biology research, though EMBL spans many additional domains.
• Broad Institute of MIT and Harvard: US biomedical and genomic research institute with significant anti-infectives and computational biology programs. Comparable to HIPS in integrating AI/ML with wet-lab drug discovery but operates at substantially larger scale and scope.
• Wellcome Sanger Institute: UK genomic and infectious disease research institute with significant anti-infectives and microbiome work. Comparable to HIPS in genomic and bioinformatics approaches to AMR, though operating at much larger institutional scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/helmholtz-hips
• Instagraminstagram.com/helmholtz_hips_de
• Xx.com/helmholtz_hips

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Helmholtz Institute for Pharmaceutical Research Saarland (HIPS)